Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy

Molecular Oncology

Volumn 9, Issue 1, 2015, Pages 204-217

  Albarakati, Nada ^a   Abdel Fatah, Tarek M A ^b   Doherty, Rachel ^a   Russell, Roslin ^c   Agarwal, Devika ^d   Moseley, Paul ^b   Perry, Christina ^a   Arora, Arvind ^a   Alsubhi, Nouf ^a   Seedhouse, Claire ^a   Rakha, Emad A ^a   Green, Andrew ^a   Ball, Graham ^d   Chan, Stephen ^b   Caldas, Carlos ^c   Ellis, Ian O ^a   Madhusudan, Srinivasan ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

Author keywords

ATM; Base excision repair; BRCA1; Chemopotentiation; Cisplatin; DNA PK; Small molecule inhibitors; Synthetic lethality

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ANTINEOPLASTIC AGENT; ATM PROTEIN; BRCA1 PROTEIN; CISPLATIN; DNA; DNA DIRECTED DNA POLYMERASE BETA; DOUBLE STRANDED DNA; KU 60019; MESSENGER RNA; NU 7026; NU 7441; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG; XRCC1 PROTEIN; ATM PROTEIN, HUMAN; BRCA1 PROTEIN, HUMAN; DNA DEPENDENT PROTEIN KINASE; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; ARTICLE; ARTIFICIAL NEURAL NETWORK; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CELL CYCLE ARREST; CHEMOSENSITIVITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GERMLINE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LETHALITY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL RATE; TISSUE MICROARRAY; UNIVARIATE ANALYSIS; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; ENZYMOLOGY; GENETICS; METABOLISM; MORTALITY; MULTICENTER STUDY; PATHOLOGY; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-ACTIVATED PROTEIN KINASE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NUCLEAR PROTEINS; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; SURVIVAL RATE;

EID: 84920421631     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.08.001     Document Type: Article

References (49)

1. Abdel-Fatah T., Sultana R., Abbotts R., Hawkes C., Seedhouse C., Chan S., Madhusudan S. Clinicopathological and functional significance of XRCC1 expression in ovarian cancer. Int. J. Cancer J. Int. du Cancer 2013, 132:2778-2786.
2. Abdel-Fatah T.M., Albarakati N., Bowell L., Agarwal D., Moseley P., Hawkes C., Ball G., Chan S., Ellis I.O., Madhusudan S. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. Breast Cancer Res. Treat. 2013, 142:515-527.
3. Abdel-Fatah T.M., Perry C., Moseley P., Johnson K., Arora A., Chan S., Ellis I.O., Madhusudan S. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. Breast Cancer Res. Treat. 2014, 143:411-421.
4. Abdel-Fatah T.M., Russell R., Agarwal D., Moseley P., Abayomi M.A., Perry C., Albarakati N., Ball G., Chan S., Caldas C., Ellis I.O., Madhusudan S. DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. Mol. Oncol. 2014, 8:520-532.
5. Abdel-Fatah T.M., Russell R., Albarakati N., Maloney D.J., Dorjsuren D., Rueda O.M., Moseley P., Mohan V., Sun H., Abbotts R., Mukherjee A., Agarwal D., Illuzzi J.L., Jadhav A., Simeonov A., Ball G., Chan S., Caldas C., Ellis I.O., Wilson D.M., Madhusudan S. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol. Oncol. 2014, pii: S1574-7891(14)00092-1. 10.1016/j.molonc.2014.04.009.
6. Alli E., Sharma V.B., Sunderesakumar P., Ford J.M. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res. 2009, 69:3589-3596.
7. Berenbaum M.C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 1981, 35:269-335.
8. Bergh J., Norberg T., Sjogren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1995, 1:1029-1034.
9. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., Loeb L.A. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. U S A 2006, 103:18238-18242.
10. Caestecker K.W., Van de Walle G.R. The role of BRCA1 in DNA double-strand repair: past and present. Exp. Cell Res. 2013, 319:575-587.
11. Chapman J.R., Taylor M.R., Boulton S.J. Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 2012, 47:497-510.
12. Clark C.C., Weitzel J.N., O'Connor T.R. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin invitro and invivo using BRCA1 and BRCA2 isogenic models. Mol. Cancer Ther. 2012, 11:1948-1958.
13. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., Graf S., Ha G., Haffari G., Bashashati A., Russell R., McKinney S., Langerod A., Green A., Provenzano E., Wishart G., Pinder S., Watson P., Markowetz F., Murphy L., Ellis I., Purushotham A., Borresen-Dale A.L., Brenton J.D., Tavare S., Caldas C., Aparicio S. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
14. De Summa S., Pinto R., Pilato B., Sambiasi D., Porcelli L., Guida G., Mattioli E., Paradiso A., Merla G., Micale L., De Nittis P., Tommasi S. Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis. 2014, 5:e1076.
15. Dejmek J., Iglehart J.D., Lazaro J.B. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol. Cancer Res. 2009, 7:581-591.
16. Dianov G.L., Hubscher U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 2013, 41:3483-3490.
17. Durant S.T., Nickoloff J.A. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle 2005, 4:1216-1222.
18. Golding S.E., Rosenberg E., Valerie N., Hussaini I., Frigerio M., Cockcroft X.F., Chong W.Y., Hummersone M., Rigoreau L., Menear K.A., O'Connor M.J., Povirk L.F., van Meter T., Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8:2894-2902.
19. Hartman A.R., Ford J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 2002, 32:180-184.
20. Hickson I., Zhao Y., Richardson C.J., Green S.J., Martin N.M., Orr A.I., Reaper P.M., Jackson S.P., Curtin N.J., Smith G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64:9152-9159.
21. Hill R., Lee P.W. The DNA-dependent protein kinase (DNA-PK): more than just a case of making ends meet?. Cell Cycle 2010, 9:3460-3469.
22. Hsu N.C., Huang Y.F., Yokoyama K.K., Chu P.Y., Chen F.M., Hou M.F. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer. PloS One 2013, 8:e56256.
23. Huen M.S., Sy S.M., Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat. Rev. Mol. Cell Biol. 2010, 11:138-148.
24. Husain A., He G., Venkatraman E.S., Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res. 1998, 58:1120-1123.
25. Lancashire L.J., Powe D.G., Reis-Filho J.S., Rakha E., Lemetre C., Weigelt B., Abdel-Fatah T.M., Green A.R., Mukta R., Blamey R., Paish E.C., Rees R.C., Ellis I.O., Ball G.R. A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res. Treat. 2010, 120:83-93.
26. Langelier M.F., Pascal J.M. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr. Opin. Struct. Biol. 2013, 23:134-143.
27. Lee J.H., Goodarzi A.A., Jeggo P.A., Paull T.T. 53BP1 promotes ATM activity through direct interactions with the MRN complex. EMBO J. 2010, 29:574-585.
28. Lee J.H., Paull T.T. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene 2007, 26:7741-7748.
29. Lemetre C., et al. Artificial neural network based algorithm for biomolecular interaction modeling. Lecture Notes in Computer Science 2009, 5517:877-885. Bio-Inspired Systems: Computational and Ambient Intellegence.
30. Lord C.J., Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 2008, 8:363-369.
31. Masaoka A., Gassman N.R., Horton J.K., Kedar P.S., Witt K.L., Hobbs C.A., Kissling G.E., Tano K., Asagoshi K., Wilson S.H. Interaction between DNA polymerase beta and BRCA1. PloS One 2013, 8:e66801.
32. Mladenov E., Iliakis G. Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. Mutat. Res. 2011, 711:61-72.
33. Nutley B.P., Smith N.F., Hayes A., Kelland L.R., Brunton L., Golding B.T., Smith G.C., Martin N.M., Workman P., Raynaud F.I. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br. J. Cancer 2005, 93:1011-1018.
34. O'Donovan P.J., Livingston D.M. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 2010, 31:961-967.
35. Pawitan Y., Bjohle J., Amler L., Borg A.L., Egyhazi S., Hall P., Han X., Holmberg L., Huang F., Klaar S., Liu E.T., Miller L., Nordgren H., Ploner A., Sandelin K., Shaw P.M., Smeds J., Skoog L., Wedren S., Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7:R953-R964.
36. Saha T., Rih J.K., Roy R., Ballal R., Rosen E.M. Transcriptional regulation of the base excision repair pathway by BRCA1. J.Biol. Chem. 2010, 285:19092-19105.
37. Schipler A., Iliakis G. DNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice. Nucleic Acids Res. 2013, 41:7589-7605.
38. Shekh K., Khan S., Jena G., Kansara B.R., Kushwaha S. 3-Aminobenzamide-a PARP inhibitor enhances the sensitivity of peripheral blood micronucleus and comet assays in mice. Toxicol. Mech. Methods 2014, 24:332-341.
39. Shiloh Y., Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 2013, 14:197-210.
40. Silver D.P., Livingston D.M. Mechanisms of BRCA1 tumor suppression. Cancer Discov. 2012, 2:679-684.
41. Smoot M.E., Ono K., Ruscheinski J., Wang P.L., Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27:431-432.
42. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 2004, 3. Article3.
43. Sultana R., Abdel-Fatah T., Abbotts R., Hawkes C., Albarakati N., Seedhouse C., Ball G., Chan S., Rakha E.A., Ellis I.O., Madhusudan S. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res. 2013, 73:1621-1634.
44. Tassone P., Di Martino M.T., Ventura M., Pietragalla A., Cucinotto I., Calimeri T., Bulotta A., Neri P., Caraglia M., Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts invivo. Cancer Biol. Ther. 2009, 8:648-653.
45. Tavecchio M., Munck J.M., Cano C., Newell D.R., Curtin N.J. Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination. Cancer Chemother. Pharmacol. 2012, 69:155-164.
46. Tibshirani R., Hastie T., Narasimhan B., Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. U S A 2002, 99:6567-6572.
47. Turner N., Tutt A., Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 2004, 4:814-819.
48. Wu L., Wang F., Xu R., Zhang S., Peng X., Feng Y., Wang J., Lu C. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res. Treat. 2013, 142:619-627.
49. Yoshida K., Ozaki T., Furuya K., Nakanishi M., Kikuchi H., Yamamoto H., Ono S., Koda T., Omura K., Nakagawara A. ATM-dependent nuclear accumulation of IKK-alpha plays an important role in the regulation of p73-mediated apoptosis in response to cisplatin. Oncogene 2008, 27:1183-1188.